VEA vs XBI
Vanguard FTSE Developed Markets ETF vs SPDR S&P Biotech ETF
- • VEA has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • VEA pays a higher dividend yield (2.46%).
Side-by-side metrics
| Metric | VEA | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.46% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $309.07B | $10.92B |
YTD return | 12.94% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.98 | 1.01 |
P/E ratio | 15.85 | — |
Last price | $69.98 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VEA top holdings
| 005930.KQ | Samsung Electronics Co Ltd | 2.81% |
| 000660.KQ | SK hynix Inc | 2.30% |
| ASML.AS | ASML Holding NV | 2.14% |
| HSBA.L | HSBC Holdings PLC | 1.05% |
| ROP.SW | Roche Holding AG Ordinary Shares new | 0.90% |
| SHEL.L | Shell PLC | 0.86% |
| RY | Royal Bank of Canada | 0.85% |
| NOVN.SW | Novartis AG Registered Shares | 0.82% |
| 8306.T | Mitsubishi UFJ Financial Group Inc | 0.78% |
| AZN.L | AstraZeneca PLC | 0.75% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VEA
VEA (Vanguard FTSE Developed Markets ETF) is Developed-market stocks outside the US and Canada. Managed by Vanguard, the fund carries $309.1B in assets under management, an expense ratio of 0.03%, a dividend yield of 2.46%. Its largest holding is Samsung Electronics Co Ltd (005930.KQ), which represents 2.8% of the portfolio. Real Estate is the fund's largest sector exposure at 2.3%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.